东方国家原发性肝癌发病趋势及影响因素

张明媛; 牛俊奇

doi:10.3969/j.issn.1001-5256.2018.07.007

东方国家原发性肝癌发病趋势及影响因素

DOI: 10.3969/j.issn.1001-5256.2018.07.007

吉林大学第一医院肝胆胰内科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2417
- HTML全文浏览量: 59
- PDF下载量: 599
- 被引次数: 0
出版历程
- 收稿日期: 2018-06-12
- 出版日期: 2018-07-20

Prevalence of primary liver cancer in Eastern countries and related influencing factors

Department of Hepatology, The First Hospital of Jilin University

摘要

摘要: 原发性肝癌是严重危害人类健康的疾病,东方国家是全世界肝癌的高发地区。世界卫生组织相关数据显示,近年来大部分东方国家的原发性肝癌发病率呈下降趋势,其中乙型肝炎疫苗接种,乙、丙型肝炎抗病毒药物的应用以及黄曲霉毒素污染减少是原发性肝癌发病率下降的主要因素;酒精性及非酒精性脂肪性肝病发病率逐年上升,其作为原发性肝癌的危险因素应引起重视。
- 肝肿瘤 /
- 发病率 /
- 危险因素
Abstract: Primary liver cancer is a serious disease which threatens human health, and Eastern countries have a high prevalence rate of primary liver cancer. Data from the World Health Organization show that in recent years, the incidence rate of liver cancer tends to decrease in most Eastern countries, and hepatitis B vaccination, application of antiviral drugs for hepatitis B and C, and reduced aflatoxin contamination are the main reasons for the reduction in the incidence rate of liver cancer. The incidence rates of alcoholic and nonalcoholic fatty liver disease are gradually increasing year by year, which should be taken seriously as a risk factor for liver cancer.
- liver neoplasms /
- incidence /
- risk factors

HTML全文

参考文献(22)

[1]FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136 (5) :e359-e386.

[2]SCHOTTENFELD D, FRAUMENI JF.Cancer epidemiology and prevention[M].3rd ed.New York:Oxford University Press, 2006.

[3]WU J, YANG S, XU K, et al.Patterns and trends of liver cancer incidence rates in Eastern and Southeastern Asian countries (1983-2007) and predictions to 2030[J].Gastroenterology, 2018, 154 (6) :1719-1728.

[4]WHO.Graphs:Time trends[EB/OL].http://ci5.iarc.fr/CI5plus/Pages/graph4_sel.aspx.

[5]NEIL DT, CHEN CJ, MICHAEL CK.Liver cancer (world cancer report) [EB/OL].http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014.

[6]ACHARYA SK.Epidemiology of hepatocellular carcinoma in India[J].J Clin Exp Hepatol, 2014, 4 (Suppl 3) :s27-s33.

[7]SRIPA B, KAEWKES S, SITHITHAWORN P, et al.Liver flukeinduces cholangiocarcinoma[J].PLo S Med, 2007, 4 (7) :e201.

[8]CHIANG CJ, YANG YW, YOU SL, et al.Thirty-year outcomes of the national hepatitis B immunization program in Taiwan[J].JAMA, 2013, 310 (9) :974-976.

[9]SUN Z, CHEN T, THORGEIRSSON SS, et al.Dramatic reduction of liver cancer incidence in young adults:28 year follow-up of etiological interventions in an endemic area of China[J].Carcinogenesis, 2013, 34 (8) :1800-1805.

[10]BARTENSCHLAGER R, BAUMERT TF, BUKH J, et al.Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy:Considerations for scientists and funding agencies[J].Virus Res, 248:53-62.

[11]LIAW YF, SUNG JJ, CHOW WC, et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl J Med, 2004, 351 (15) :1521-1531.

[12]KUMADA T, TOYODA H, TADA T, et al.Effect of nucleos (t) ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients:A propensity score analysis[J].J Hepatol, 2013, 58 (3) :427-433.

[13]IKEDA K, KAWAMURA Y, KOBAYASHI M, et al.Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma[J].Dig Dis Sci, 2017, 62 (10) :2932-2942.

[14]LEE SH, JIN YJ, SHIN JY, et al.Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs[J].Medicine (Baltimore) , 2017, 96 (1) :e5321.

[15]KANWAL F, KRAMER J, ASCH SM, et al.Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents[J].Gastroenterology, 2017, 153 (4) :996-1005.

[16]LI DK, REN Y, FIERER DS, et al.The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals:An ERCHIVES study[J].Hepatology, 2018, 67 (6) :2244-2253.

[17]WHO.Global health sector strategy on viral hepatitis 2016-2021[EB/OL].http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en.

[18]WU J, XU H, HE X, et al.Six-year changes in the prevalence of obesity and obesity-related diseases in Northeastern China from2007 to 2013[J].Sci Rep, 2017, 7:41518.

[19]MAROT A, HENRION J, KNEBEL JF, et al.Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis:An observational study[J].PLo S One, 2017, 12 (10) :e0186715.

[20]WHO.Global status report on alcohol and health[EB/OL].http://www.who.int/topics/alcohol_drinking/en.

[21]WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:The major impact of China[J].Hepatology, 2014, 60 (6) :2099-2108.

[22]Global Burden of Disease Liver Cancer Collaboration, AKINYEMIJU T, ABERA S, et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level:Results from the Global Burden of Disease Study 2015[J].JAMA Oncol, 2017, 3 (12) :1683-1691.

施引文献

资源附件(0)

访问统计